Journal of Proteomics and Genomics Research
Open Access
Determination of the Proteomic Response to Lapatinib Treatment using a Comprehensive and Reproducible Ion-Current-Based Proteomics Strategy
Sep 2013 DOI 10.14302/issn.2326-0793.jpgr-13-257
Kathleen O’ConnellCorresponding author
Lapatinib, a small molecule tyrosine kinase inhibitor is currently used in the treatment of HER2-positive breast cancer. The aim of this study was to further understanding of lapatinib response for the development of novel treatment lapatinib-focussed treatment strategies. HER2-overexpressing SKBR3…